For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.
BPC-157 + TB-500
Regenerative Peptide Blend
Dosage
Quantity
Price
$98.99
Free shipping on orders $150+
60-day money-back guarantee
Secure checkout
Made in the USA
Certificate of Analysis
Batch verified lab data
99.93%
Purity
- Variant
- BPC-157 + TB-500 10mg (5 + 5)
- Lot #
- A0112
- Labeled
- 20mg
- Actual
- 22.56mg
- Tested
- Feb 4, 2026
Frequently Researched Together
View allResearch Purposes Snapshot
This SKU pairs BPC-157 with TB-500 (a Tβ4-related fragment). Published work is almost entirely on each peptide alone; formal combination safety or efficacy trials are uncommon. Not FDA approved.
Blend rationale
Dual regenerative pathways
Stacks are discussed because vascular recruitment (BPC-weighted narratives) and motility/actin programs (TB-weighted narratives) are viewed as orthogonal levers—still hypothetical without matched combo cohorts.
- BPC-157 — VEGFR2 / angiogenesis emphasis in many reviews
- TB-500 — actin organization / ILK-linked migration emphasis
- Overlap — anti-inflammatory phenotypes cited across both archives
Educational summaries (e.g. GlobalRPH-style reviews) collate figures—always verify in primaries.
370+
Combined literature
Rough sum of commonly quoted publication counts (~200+ BPC-157, ~170+ TB-500).
2
Pathway layers
VEGFR2-driven perfusion narratives plus actin/ILK motility programs.
7×
BPC-157 GHR
Growth hormone receptor induction by day 3 in tendon fibroblast reports.
61%
TB-500 resurfacing
Faster re-epithelialization vs saline at day 7 in classic wound models.
No LD50
Acute tox (BPC)
Rodent packages often fail to define a classical lethal dose; TB-500 Phase 1 reported no serious events.
BPC-157 component
VEGFR2 → Akt → eNOS cascade
Reviews credit BPC-157 with amplifying VEGFR2 signaling, downstream Akt/eNOS phosphorylation, and nitric oxide availability to support perfusion in ischemic-tissue models.
TB-500 component
Actin cytoskeleton & ILK programs
Thymosin β4 fragments are repeatedly tied to G-actin sequestration, lamellipodia formation, and integrin-linked kinase activation in cardiac and dermal repair models.
Why researchers discuss pairing
Complementary regenerative angles
One line of reasoning holds that improving perfusion (BPC-weighted) supports the same niches where accelerated migration (TB-weighted) is measured—both also carry anti-inflammatory descriptors in animal literature.
Synergy framing: vascular delivery hypotheses plus motility hypotheses are mechanistically plausible yet unproven as a fixed-ratio product without dedicated trials.
- BPC-157 primary
- Angiogenesis / VEGF axis
- TB-500 primary
- Cell migration / actin
- Shared motif
- Anti-inflammatory modulation in multiple preclinical readouts
Component metrics (isolated studies)
Preclinical highlights
Fold-change exceeds bar scale—see original assays.
Convergent angiogenesis + inflammation language appears across reviews (e.g. GlobalRPH 2025 summaries)—still not a combination RCT.
Human + program anchors
What exists in clinic files
- BPC-157: ~7× GHR signal (day 3 tendon tissue, model dependent).
- TB-500 Phase 1: no serious adverse events across 42–1260 mg IV arms; full completion reported.
- TB-500 ophthalmic: Phase 2 dry-eye program completed per sponsor disclosures.
No large, peer-reviewed combination safety study is cited in mainstream summaries—infer synergy cautiously.
Healing acceleration (components)
Directional model outcomes
- BPC-157 — tendon transection~50% faster
- TB-500 — re-epithelialization (7 d)+61%
- BPC-157 — wound closure~45% faster
- TB-500 — neuro functional gain~35%
- BPC-157 — muscle repair models~40% faster
J Appl Physiol (2011) and wound literature for BPC metrics.
Application themes
Tendon & ligament
Complementary matrix cues — J Appl Physiol lineage.
Wound healing
61% resurfacing + perfusion hypotheses — J Invest Dermatol.
Muscle recovery
FAK/paxillin vs actin regulation — Expert Opin Biol Ther.
Anti-inflammatory
Parallel pathway dampening — PMC reviews.
Musculoskeletal depth
BPC-157 is tied to angiogenic support and fibroblast stress survival; TB-500 amplifies keratinocyte and mesenchymal motility readouts in separate assays.
- BPC migration (tendon fibroblasts) ≈ +70%
- TB keratinocyte migration ≈ +200%
- BPC survival under oxidative challenge ≈ +60%
GlobalRPH / education collations — confirm in primary PDFs.
Cardiovascular overlap
- TB-500 — ILK activation, cardiomyocyte migration (Nature, 2004)
- BPC-157 — VEGFR2-linked vascular repair narratives
- Both — anti-inflammatory descriptors in injury models
Gastrointestinal (BPC-weighted)
Gastric-juice origin plus 24+ hour simulated stability supports GI-focused study lines that may parallel TB tissue-repair motifs.
World J Gastroenterol.
Neurological
TB-500 literature emphasizes oligodendrocyte expansion from SVZ niches; BPC-157 reviews cite brain–gut signaling modulation in rodent stress models.
Safety profile from research
Aggregated from individual peptide datasets—combination files remain sparse.
Injection site
MildHeadache
MildGI discomfort
MildUpper respiratory
MildDual pro-angiogenic caution
Because both peptides are discussed as pro-repair and pro-perfusion, oncology screens are a reasonable research planning step even though dedicated cancer trials are lacking.
Component safety anchors
- BPC-157 — no classical LD50 in rodent tox panels cited
- TB-500 — 0 serious AEs in Phase 1 IV narratives
- TB-500 — 0 dose-limiting toxicities in published escalation
- BPC-157 — no consistent organ toxicity pattern in summaries
Regulatory & sourcing
- Both APIs are unapproved drugs when sold for human use in the U.S.
- WADA lists both under S0; DoD supplement list also flags related compounds.
- Australia / New Zealand scheduling treats certain peptides as Rx-only—still not a consumer green light.
- Active malignancy, pregnancy, lactation = insufficient data.
- Unverified vendors amplify impurity risk—demand CoA + mass spec traceability.
Storage handling reference
Peptide handling
Freeze
Powder: −20°C or colder.
Reconstitute
Sterile workflow per SOP.
Light
Minimize UV during prep.
Aliquot
Limit freeze-thaw cycles.
Researcher notes
- No dedicated combination PK/tox study is widely cited—assume independence until proven.
- Individual peptide profiles look comparatively favorable in their respective archives.
- Dual angiogenesis narratives warrant conservative monitoring in any translational planning.
Important Research Notice
Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.